Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Cents and Sensibility - Kimberly and Friends' Consortium -- Ignore unavailable to you. Want to Upgrade?

To: Bouf who wrote (75971)	2/16/2000 1:01:00 PM
From: StocksDATsoar	Respond to of 108040

This is huge for BSDM...Also read they're other news releases...WOW. BSDM: this is a fact, no doubt. Please read their PR: biz.yahoo.com ******* Wednesday February 16, 8:09 am Eastern Time Company Press Release SOURCE: BSD Medical Corporation National Television to Feature BSD Medical and Hyperthermia SALT LAKE CITY, Feb. 16 /PRNewswire/ -- BSD Medical Corp. (OTC Bulletin Board: BSDM - news) announced today an upcoming national CNBC airing of a broadcast featuring BSD Medical Corporation and Hyperthermia. The program will be featured on the Emmy award-winning series, ``Today's Health,' discusses how Hyperthermia can enhance existing therapies such as surgery, chemotherapy, radiation and biological therapies, and how this innovative treatment can bring new hope and improved survival for people suffering from cancer. In introducing Hyperthermia, broadcast journalist and show host Faith Daniels states, ``The struggle against cancer requires our best and brightest innovations. Hyperthermia is another powerful treatment that gives us one more weapon against the second leading cause of death in America. This promising therapy uses focused heat, and the result may be widespread hope.' The program (which will air coast-to-coast on CNBC Sunday, February 20th at 1:30 p.m. Eastern, 12:30 p.m. Central, 11:30 a.m. Mountain and 10:30 a.m. Pacific Time) draws on the clinical experience and insights of medical experts around the world. Dr. Gerard van Roon of Rotterdam says, ``The power of Hyperthermia is that it increases the effect of conventional techniques such as radiotherapy (radiation) or chemotherapy. Besides enhancing the effects, it has no toxicity, so it does not harm the patient.' Regarding this increased effect, Dr. Clare Vernon from London states, ``Hyperthermia trials are consistently showing a 20-30% improvement on the treatment results we had before, and that is such a big improvement.' Speaking on the clinical applications of Hyperthermia, Dr. Ajmel Puthawala of Long Beach Memorial Hospital said, ``Head and neck cancers, breast cancers, some pelvic cancers like prostate cancer and gynecologic cancers are the sites that can be treated well with Hyperthermia.' The program demonstrates the BSD-2000, explaining that ``the treatment of cancer using Hyperthermia relies on advanced equipment, like the BSD-2000 developed by BSD Medical Corporation. The BSD-2000 can precisely deliver heat treatments into the malignant region without harming healthy tissue.' Dr. Steven Stroup of Nashville explains BSD-2000 treatment planning. ``You take a look at the body in sections,' he says, ``like we do with CT scans or MRI scans, and you can study, three dimensionally, the tumor in the normal tissue. Then you do planning. You do mock computerized setups of heating and look at heating patterns in those patients. That gives you an ability to plan your heating deposition and steer that heating to exactly where you want it.' Regarding further sophistication of the BSD-2000, a pre-broadcast press release from Five Star Productions states, ``Much of BSD Medical's equipment has already received FDA approval, and the company continues to aggressively advance the state-of-the-art of Hyperthermia treatment with new equipment. The new BSD-2000-3D/MR, for example, combines the high technology concepts of 3-D heating pattern shaping, 3-D patient-specific treatment planning and Magnetic Resonance Imaging (MRI).' Hyrum Mead, President of BSD Medical Corporation said, ``the timing of this broadcast is perfect. We have scarcely announced receipt of the CE Mark for the BSD-2000, and now the product is being given national exposure through a CNBC airing. From a marketing perspective, the CE Mark provides in Europe the same advantage as an FDA approval in the United States.' We have obtained rights to reproduction and distribution of this program and feel that it has great potential for use both in the United States and abroad. Statements contained in this press release that are not historical facts are forward looking statements, as that item is defined in the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to risks and uncertainties (detailed in the Company's findings with the Securities and Exchange Commission) that could cause actual results to differ materially from estimated results. SOURCE: BSD Medical Corporation